Navigation Links
Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
Date:11/24/2009

ain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner or commercialize lorcaserin or other of its compounds or programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; Arena's ability to obtain additional funds; Arena's ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.


Contact: Arena Pharmaceuticals, Inc.
Jack Lief
President and CEO

Cindy McGee
Manager, IR and Corporate Communications
858.453.7200, ext. 1479

Media Contact: Russo Partners
David Schull, President
'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... MONMOUTH JUNCTION, N.J. , Aug. 27, 2014 /PRNewswire/ ... developing innovative drug delivery technologies, today announced that it ... New Jersey Business & Industry Association,s 2014 Awards ... Finalists were selected by an independent panel of judges ... member company volunteers. Award winners will be honored at ...
(Date:8/27/2014)... White City, OR (PRWEB) August 27, 2014 ... it stands to reason that the next beverage craze ... Force Technology announced today that formulators can use Stress ... any ingredient used in the making of a beverage, ... natural release for stress-generated energy, channeling that power into ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 WriteResult, LLC ... – has once again shown superiority when it comes ... by completing the ePRO portion of their most recent ... The Japan-based pharma chose WriteResult’s digital writing platform to ... – the first to complete drew data from a ...
(Date:8/26/2014)... , Aug. 26, 2014  NeuroSigma, Inc., a ... to develop bioelectronic technologies, today announced that it has ... U.S. Securities and Exchange Commission relating to a proposed ... of shares to be offered and the price range ... Jefferies LLC will act as the book-running ...
Breaking Biology Technology:Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... LONDON, May 3, 2012 Silence Therapeutics ... company , notes that its partner, Quark Pharmaceuticals , ... with Pfizer. This amendment will enable Quark to perform a ... in a new indication, looking at visual function in patients ...
... 2, 2012 Genomic Health, Inc. (Nasdaq: ... a strategic alliance to use Next Generation Sequencing (NGS) ... clinical development of OncoMed,s  novel antibody cancer therapeutics. ... provide Genomic Health with breast, prostate, colon and lung ...
... April 30, 2012) Barrow Neurological Institute researchers Jorge Otero-Millan, ... of the Journal of Neuroscience in a ... Barrow is part of St. Joseph,s Hospital and Medical ... laboratory, explores the neural bases of illusory motion in ...
Cached Biology Technology:Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 2Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 3Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 4Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 5Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing 2Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing 3Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing 4Barrow researchers unravel illusion 2
(Date:8/27/2014)... Gamblers are greedy bird-brains, University of Warwick research finds ... when they make risky decisions, new research has shown. ... University of Warwick,s Department of Psychology, conducted tests that ... more likely to gamble for high-value than low-value rewards. ... argue that the test results show the important role ...
(Date:8/26/2014)... a colony of harmful bacteria, biofilms make the ... in a biofilm pose a significant health risk ... treatment, and biofilm-protected bacteria account for some 80 ... are 50 to 1,000 times more resistant to ... we may have stumbled onto a magic bullet," ...
(Date:8/26/2014)... pressure from policymakers, consumers, and suppliers has prompted ... reducing the pollutants they emit from their smokestacks ... must also assess environmental performance at every step ... materials to the use and recycling of their ... the discipline known as life cycle engineering, which ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3Yale journal explores advances in sustainable manufacturing 2
... grain production must double by 2050 to address rising ... Illinois suggests crop yields will suffer unless new approaches ... Improved agronomic traits responsible for the remarkable increases in ... their ceiling for some of the world,s most important ...
... Ind. - Chemical engineers at Purdue University have developed ... biomass into biofuels, and they are proposing the creation ... to produce the fuels. "What,s important is ... -- wood chips, switch grass, corn stover, rice ...
... LAFAYETTE, Ind. - A Purdue University researcher can better retrieve ... using a newly developed technique and synthetic nanopolymer. W. ... be mapped and analyzed to find ways to inhibit the ... must be fished out of a sea of thousands of ...
Cached Biology News:'Business as usual' crop development won't satisfy future demand 2'Business as usual' crop development won't satisfy future demand 3New biofuels processing method for mobile facilities 2New biofuels processing method for mobile facilities 3New retrieval method makes studying cancer proteins easier 2
... These 1.5L PYREX trypsinizing ... homogenous tissue samples into cell ... proteins. Heavy beaded neck accepts ... enhance vigorous agitation. • Height ...
... For the efficient enrichment of functional ... or cell culture. The isolated ER ... and metabolic pathway analysis. Metabolic abnornalities ... in children, cystic fibrosis and many ...
Plasmid expressing PLAP reporter gene....
Plasmid expressing the LacZ reporter gene....
Biology Products: